Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for recurrent IgA nephropathy after kidney transplantation
ChiCTR2400084654Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of telitacicept in IgA nephropathy (IgAN) (2 arms), sponsored by Tongji Hospital. Primary endpoint: 24-hour urinary protein quantification. Planned start May 2024; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2400084654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084654.